If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

Conclusions

$32.00 plus tax (Refund Policy)

Buy Article:

Abstract:

The OECD project on pharmaceutical pricing policy has taken a close look at the evolving market for pharmaceutical products and the ways in which pricing policies serve to shape that market, yielding a number of conclusions. As tools for meeting a range of pharmaceutical policy objectives, the approaches most widely used in OECD countries to arrive at prices for pharmaceuticals ‐ external and internal price referencing ‐ are problematic in a number of respects. International price benchmarking (or external referencing) is readily gameable by the pharmaceutical industry and ‐ by reducing firms' willingness to price to market ‐ contributes to access and affordability problems in the lower‐income OECD countries, some of which spend close to a third of their health‐care resources on pharmaceuticals.

Document Type: Review Article

Publication date: September 1, 2008

Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more